- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04383977
Apatinib and Etoposide Capsule Versus Apatinib in Patients With Platinum Resistant Ovarian Cancer
May 9, 2020 updated by: Jiangsu HengRui Medicine Co., Ltd.
A Phase 2 Randomized, Open-label, Multicenter Trial of Apatinib and Etoposide Capsule Versus Apatinib in Patients With Platinum Resistant or Refractory Ovarian Cancer
The study is conducted to evaluate the efficacy, safety and tolerability of apatinib (375 mg qd) or apatinib (375 mg qd) and etoposide capsule (50 mg/d, d1-14, q3w) in subjects with platinum resistant or refractory ovarian cancer compared with apatinib (375 mg qd).
Study Overview
Status
Unknown
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Anticipated)
54
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Zhaoyu Zhong, M.M
- Phone Number: +86 15045090779
- Email: zhongzhaoyu@hrglobe.cn
Study Contact Backup
- Name: Fenglin She, M.M
- Phone Number: +86 18301190515
- Email: shefenglin@hrglobe.cn
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
Female
Description
Inclusion Criteria:
- Female patients, ≥18 Years.
- Epithelial ovarian, fallopian tube or primary peritoneal cancer
- Platinum refractory and resistant disease (disease progression during platinum therapy or within <6 months of platinum therapy)
- EOCG performance status of 0-2
Exclusion Criteria:
- Non-epithelial tumours
- Ovarian tumours with low malignant potential
- Surgery (including open biopsy) within 4 weeks before starting study therapy or anticipated need for major surgery during study treatment
- Evidence of rectosigmoid involvement by pelvic examination, bowel involvement on computed tomography, or clinical symptoms of bowel obstruction.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Apatinib-Etoposide capsule
Apatinib (375 mg qd, q3w) and Etoposide capsule(50 mg/d, d1-14, q3w) combination until disease progression or intolerable toxicity
|
Apatinib (375 mg qd, q3w) and Etoposide capsule(50 mg/d, d1-14, q3w) combination until disease progression or intolerable toxicity
|
Active Comparator: Apatinib
Apatinib (375 mg qd, q3w) until disease progression or intolerable toxicity
|
Apatinib (375 mg qd, q3w) until disease progression or intolerable toxicity
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Objective response rate (ORR) by investigator
Time Frame: up to 2 years
|
ORR was defined as the proportion of subjects who have a complete or partial response relative to baseline .
|
up to 2 years
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
AEs+SAEs
Time Frame: 30 days after the last dose
|
Frequency and severity of Adverse Events or Serious Adverse Events as defined by CTCAE version 5.0
|
30 days after the last dose
|
PFS by investigator
Time Frame: up to 2 years
|
PFS was defined as the time from the date of randomization to the first documented disease progression or death, whichever occurred first.
Progression was based on tumor assessment made by the investigator according to the RECIST criteria.
|
up to 2 years
|
Overall Survival (OS)
Time Frame: up to 3 years
|
OS is the time interval from the date of randomization to death from any cause.
|
up to 3 years
|
Pharmacokinetic characteristic
Time Frame: up to 2 years
|
Evaluation of PK parameters Tmax of apatinib or etoposide in plasma
|
up to 2 years
|
Pharmacokinetic characteristic
Time Frame: up to 2 years
|
Evaluation of PK parameters Cmax of apatinib or etoposide in plasma
|
up to 2 years
|
Pharmacokinetic characteristic
Time Frame: up to 2 years
|
Evaluation of PK parameters t1/2 of apatinib or etoposide in plasma
|
up to 2 years
|
Pharmacokinetic characteristic
Time Frame: up to 2 years
|
Evaluation of PK parameters AUC0-t of apatinib or etoposide in plasma
|
up to 2 years
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Anticipated)
May 1, 2020
Primary Completion (Anticipated)
December 1, 2020
Study Completion (Anticipated)
June 1, 2021
Study Registration Dates
First Submitted
May 6, 2020
First Submitted That Met QC Criteria
May 9, 2020
First Posted (Actual)
May 12, 2020
Study Record Updates
Last Update Posted (Actual)
May 12, 2020
Last Update Submitted That Met QC Criteria
May 9, 2020
Last Verified
May 1, 2020
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Neoplasms by Histologic Type
- Neoplasms
- Urogenital Neoplasms
- Neoplasms by Site
- Carcinoma
- Neoplasms, Glandular and Epithelial
- Genital Neoplasms, Female
- Endocrine System Diseases
- Ovarian Diseases
- Adnexal Diseases
- Gonadal Disorders
- Endocrine Gland Neoplasms
- Ovarian Neoplasms
- Carcinoma, Ovarian Epithelial
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Antineoplastic Agents
- Antineoplastic Agents, Phytogenic
- Topoisomerase II Inhibitors
- Topoisomerase Inhibitors
- Protein Kinase Inhibitors
- Etoposide
- Apatinib
Other Study ID Numbers
- Ahead-OC-203
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
IPD Plan Description
All clinical study findings and documents will be regarded as confidential.
The investigator and members of his/her research team must not disclose such information without prior written approval from the sponsor.
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Ovarian Cancer
-
Roswell Park Cancer InstituteCompletedFallopian Tube Carcinoma | Primary Peritoneal Carcinoma | Stage IIA Ovarian Cancer | Stage IIB Ovarian Cancer | Stage IIC Ovarian Cancer | Stage IIIA Ovarian Cancer | Stage IIIB Ovarian Cancer | Stage IIIC Ovarian Cancer | Stage IV Ovarian Cancer | Stage IA Ovarian Cancer | Stage IB Ovarian Cancer | Stage IC... and other conditionsUnited States
-
City of Hope Medical CenterNational Cancer Institute (NCI)CompletedCancer Survivor | Stage IIIA Ovarian Epithelial Cancer | Stage IIIB Ovarian Epithelial Cancer | Stage IIIC Ovarian Epithelial Cancer | Stage IIA Ovarian Epithelial Cancer | Stage IIB Ovarian Epithelial Cancer | Stage IIC Ovarian Epithelial Cancer | Stage IA Ovarian Epithelial Cancer | Stage IB Ovarian... and other conditionsUnited States
-
Massachusetts General HospitalJohns Hopkins University; M.D. Anderson Cancer Center; National Cancer Institute... and other collaboratorsRecruitingOvarian Neoplasms | Fallopian Tube Neoplasms | Stage III Ovarian Cancer AJCC v8 | Stage IIIA Ovarian Cancer AJCC v8 | Stage IIIA1 Ovarian Cancer AJCC v8 | Stage IIIA2 Ovarian Cancer AJCC v8 | Stage IIIB Ovarian Cancer AJCC v8 | Stage IIIC Ovarian Cancer AJCC v8 | Stage IV Ovarian Cancer AJCC v8 | Stage... and other conditionsUnited States
-
Gynecologic Oncology GroupNational Cancer Institute (NCI)CompletedOvarian Clear Cell Cystadenocarcinoma | Ovarian Endometrioid Adenocarcinoma | Ovarian Seromucinous Carcinoma | Ovarian Serous Cystadenocarcinoma | Stage IV Ovarian Germ Cell Tumor | Ovarian Sarcoma | Malignant Ovarian Epithelial Tumor | Ovarian Carcinosarcoma | Ovarian Brenner Tumor | Ovarian Mucinous... and other conditionsUnited States
-
Eve RodlerNot yet recruitingBreast Cancer | Ovarian Cancer | Breast Neoplasm | Breast Carcinoma | Breast Cancer Stage IV | Breast Cancer Stage I | Breast Cancer Stage II | Invasive Breast Cancer | Cancer, Breast | Breast Cancer Stage III | Ovary Cancer | Malignant Tumor of Breast | Ovarian Cancer Stage IIIC | Ovarian Cancer Stage IV | Ovarian Cancer... and other conditionsUnited States
-
Gynecologic Oncology GroupNational Cancer Institute (NCI)RecruitingStage IIIA Ovarian Cancer | Stage IIIB Ovarian Cancer | Stage IIIC Ovarian Cancer | Stage IV Ovarian CancerUnited States
-
Gynecologic Oncology GroupNational Cancer Institute (NCI)CompletedStage IIA Fallopian Tube Cancer | Stage IIA Ovarian Cancer | Stage IIB Fallopian Tube Cancer | Stage IIB Ovarian Cancer | Stage IIC Fallopian Tube Cancer | Stage IIC Ovarian Cancer | Stage IIIA Fallopian Tube Cancer | Stage IIIA Ovarian Cancer | Stage IIIA Primary Peritoneal Cancer | Stage IIIB Fallopian... and other conditionsUnited States
-
University of WashingtonNational Cancer Institute (NCI)CompletedCaregiver | Stage IIIA Ovarian Cancer | Stage IIIB Ovarian Cancer | Stage IIIC Ovarian Cancer | Stage IV Ovarian CancerUnited States
-
Sidney Kimmel Cancer Center at Thomas Jefferson...CompletedStage I Breast Cancer | Stage I Uterine Corpus Cancer | Stage II Uterine Corpus Cancer | Stage III Uterine Corpus Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIA Breast Cancer | Stage IIB Breast Cancer | Stage... and other conditionsUnited States
-
University of WashingtonMinnesota Ovarian Cancer AllianceTerminatedStage III Ovarian Cancer AJCC v8 | Stage IIIA Ovarian Cancer AJCC v8 | Stage IIIA1 Ovarian Cancer AJCC v8 | Stage IIIA2 Ovarian Cancer AJCC v8 | Stage IIIB Ovarian Cancer AJCC v8 | Stage IIIC Ovarian Cancer AJCC v8 | Stage IV Ovarian Cancer AJCC v8 | Stage IVA Ovarian Cancer AJCC v8 | Stage IVB Ovarian... and other conditionsUnited States
Clinical Trials on Apatinib and Etoposide capsule
-
Henan Cancer HospitalJiangsu HengRui Medicine Co., Ltd.UnknownSmall Cell Lung CancerChina
-
Third Military Medical UniversityNot yet recruiting
-
Qingdao UniversityUnknownProgression Free SurvivalChina
-
Cancer Institute and Hospital, Chinese Academy...Completed
-
Sichuan Cancer Hospital and Research InstituteUnknownLung Cancer | Extensive-stage Small Cell Lung CancerChina
-
Zhou ChengzhiJiangsu Hengrui Pharmaceutical Co., Ltd.RecruitingExtensive Stage Small Cell Lung CancerChina
-
Fuzhou General HospitalUnknownSmall Cell Lung Cancer | Lung Neoplasm | PD-1 InhibitorsChina
-
Peking University People's HospitalPeking University Shougang HospitalCompletedEffect of Drug | Toxicity, Drug | Secondary ResistanceChina
-
Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator...UnitedHealthcareActive, not recruitingSmall Cell Lung CancerUnited States
-
Beijing Sanbo Brain HospitalRecruitingRecurrent MedulloblastomaChina